U.S. Homebuyers Are Getting Discouraged by Rising Rates and Prices

image

(Bloomberg) — Potential home buyers are getting discouraged by rising mortgage rates and home prices, according to a survey released on Monday by the New York Federal Reserve.

U.S. consumers expect mortgage rates to increase substantially over the next several years, with households on average projecting rates of 6.7% a year from now and 8.2% in three years, the survey shows.

The average probability of buying a home if a household moved over the next three years dropped sharply to 60.7% from 68.5% in 2021, marking the first decline since the annual housing survey started in 2014.

Respondents said they still view home ownership as a smart financial investment, but the outlook weakened slightly. About 71% of respondents said they thought buying property in their zip code was a “very good” or “somewhat good” investment, down from the survey high of 73.6% seen last year. The share of people who viewed housing as a bad investment ticked up to 9.9% from 6.5% a year ago.

U.S. 30-year mortgage rates are surging this year and topped 5% this month for the first time in more than a decade, according to Freddie Mac. They are expected to keep climbing as the Fed pivots to combating the hottest inflation seen in four decades. The Fed raised its benchmark interest rate in March for the first time since 2018 and officials are expected to keep hiking for the rest of the year.

But consumers expect home prices to keep rising even as borrowing costs increase. Respondents surveyed by the New York Fed said they anticipate home prices in their zip code to rise by 7% on average over the next year, up from the 5.7% growth expected last year.

Renters aren’t anticipating any relief in the near term, either. Households said they see rents rising by 11.5% over the next year, up from 6.6% last year.

©2022 Bloomberg L.P.

 
Trending Ideas

Featured Stocks On The Move

Daily Rundown

Top 3 Stocks in Leading Sectors
  • 3 Software Stocks To Buy Now

    International Business Machines Corporation (IBM) International Business Machines Corporation (IBM) is a global leader in cloud computing, AI, and enterprise software. The company provides IT infrastructure, cybersecurity, and quantum computing... Read More

  • 3 Food Stocks To Buy Now

    The Campbell’s Company (CPB) The Campbell’s Company is a leading producer of packaged foods and beverages, known for its soups, sauces, and snacks. With brands like Campbell’s, Pepperidge Farm, and... Read More

  • 3 Utility Stocks To Buy Now

    IDACORP, Inc. (IDA) IDACORP, Inc. is a utility holding company that provides electricity through its subsidiary, Idaho Power. The company focuses on renewable energy initiatives, grid modernization, and sustainable power... Read More

  • 3 Biotechnology Stocks To Buy Now

    Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative injectable drug formulations. Its proprietary technology enhances drug stability and... Read More

  • 3 Consumer Service Stocks To Buy Now

    TripAdvisor, Inc. (TRIP) TripAdvisor, Inc. operates the world’s largest travel guidance platform, offering user-generated reviews, price comparisons, and booking services for hotels, attractions, and restaurants worldwide. Chart Wynn Resorts, Limited... Read More

  • 3 Software Stocks To Buy Now

    Udemy, Inc. (UDMY) Udemy, Inc. is an online learning platform offering a vast catalog of courses across various fields. The company connects learners with expert instructors, providing affordable and accessible... Read More

  • 3 Energy Stocks To Buy Now

    Ranger Energy Services, Inc. (RNGR) Ranger Energy Services, Inc. provides well services and support for oil and gas production. The company specializes in high-spec rig solutions, completion services, and workover... Read More

  • 3 Pharmaceutical Stocks To Buy Now

    ACADIA Pharmaceuticals Inc. (ACAD) ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company’s lead product, NUPLAZID, is used to treat Parkinson’s... Read More